Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Ronan McLaughlin

Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Ronan McLaughlin

NeoPancONE
GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
Best of ASCO® Toronto Conference 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Co-Chairs

Dr. Aly-Khan Lalani

Dr. Natasha Leighl

Icon Chair Speaker

Speakers

Dr. Ronan McLaughlin

Studies / Trials Discussed

NeoPancONE
GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.

Studies/trials discussed:

NeoPancONE GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
Tagged